Drugs / 89Zr-DFOsq-olaratumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06537596 | Oct 2024 → Mar 2026 overdue | soft tissue sarcoma | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFOsq-olaratumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06537596 ↗ |
| Known as | 89Zr-TLX300-CDx | “89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)” NCT06537596 ↗ |
| Target | PDGFRA | “Olaratumab is a PDGFRα-targeted antibody” NCT06537596 ↗ |